Na Li

Na Li

Auto-generated profile, based on publicly available information

Na Li

School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Acta Biomaterialia
Verified
Journal Article
Open access
SPSara Pereira
Sara Pereira
GMGuanglong Ma
Guanglong Ma
LNLi Na
Li Na
SHSamo Hudoklin
Samo Hudoklin
MKMateja E. Kreft
Mateja E. Kreft
WAWafa Al-Jamal
Wafa Al-Jamal
L-377,202 prodrug consists of doxorubicin (Dox) conjugated to a prostate-specific antigen (PSA) peptide substrate that can be cleaved by enzymatically active PSA at the tumor site. Despite the initial promise in phase I trial, further testing of L-377,202 (herein called Dox-PSA) was ceased due to some degree of non-specific activation and toxicity concerns. To improve safety of Dox-PSA, we encapsulated it into low temperature-sensitive liposomes (LTSL) to bypass systemic activation, while maintaining its biological activity upon controlled release in response to mild hyperthermia (HT). A time-dependent accumulation of activated prodrug in the nuclei of PSA-expressing cells exposed to mild HT was observed, showing that Dox-PSA was efficiently released from the LTSL, cleaved by PSA and entering the cell nucleus as free Dox. Furthermore, we have shown that Dox-PSA loading in LTSL can block its biological activity at 37°C, while the combination with mild HT resulted in augmented cytotoxicity in both 2D and 3D PC models compared to the free Dox-PSA. More importantly, Dox-PSA encapsulation in LTSL prolonged its blood circulation and reduced Dox accumulation in the heart of C4-2B tumor-bearing mice over the free Dox-PSA, thus significantly improving Dox-PSA therapeutic window. Finally, Dox-PSA-loaded LTSL combined with HT significantly delayed tumor growth at a similar rate as mice treated with free Dox-PSA in both solid and metastatic PC tumor models. This indicates this strategy could block the systemic cleavage of Dox-PSA without reducing its efficacy in vivo, which could represent a safer option to treat patients with locally advanced PC. STATEMENT OF SIGNIFICANCE: This study investigates a new tactic to tackle non-specific cleavage of doxorubicin PSA-activatable prodrug (L-377,202) to treat advanced prostate cancer. In the present study, we report a nanoparticle-based approach to overcome the non-specific activation of L-377,202 in the systemic circulation. This includes encapsulating Dox-PSA in low temperature-sensitive liposomes to prevent its premature hydrolysis and non-specific cleavage. This class of liposomes offers payload protection against degradation in plasma, improved pharmacokinetics and tumor targeting, and an efficient and controlled drug release triggered by mild hyperthermia (HT) (∼42°C). We believe that this strategy holds great promise in bypassing any systemic toxicity concerns that could arise from the premature activation of the prodrug whilst simultaneously being able to control the spatiotemporal context of Dox-PSA cleavage and metabolism.

30 April 2026 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
NLNa Li
Na Li
WAWafa Al-Jamal
Wafa Al-Jamal
Human serum albumin (HSA) nanoparticles are promising drug carriers; however, robust control of their physicochemical and biological properties remains challenging. Here, we investigate how formulation parameters, mixing regime and crosslinking chemistry govern HSA nanoparticles' biological performance. Glutaraldehyde (GA)-crosslinked HSA nanoparticles were first optimised using a bulk desolvation process by varying HSA concentration, pH and desolvation solvent. The formulation was then translated to a staggered herringbone micromixer to tune particle size via total flow rate and flow rate ratio. In parallel, a crosslinker-free route based on glutathione (GSH)-mediated disulfide reorganization, with or without H2O2, was developed, in which GSH transiently reduces intramolecular disulfide bonds and subsequent oxidation forms stabilising intermolecular disulfides. GA-crosslinked and GSH-mediated disulfide-crosslinked HSA nanoparticles were compared in terms of colloidal and serum stability, cytotoxicity and cellular uptake in 4T1 breast cancer cells, and curcumin was encapsulated as a model hydrophobic drug. Both strategies produced physically stable nanoparticles, curcumin-loaded nanoparticles with good drug loading. In carrier-focused evaluations, GA-crosslinked HSA nanoparticles exhibited smaller sizes, negative charge, and high biocompatibility, with sustained cellular uptake and minimal serum-induced aggregation. In contrast, GSH-based HSA NPs were strongly cationic, exhibited faster initial cellular uptake, and underwent pronounced serum-mediated charge reversal, under the tested conditions. Using curcumin (CCM) as a model hydrophobic payload, both formulations achieved effective drug encapsulation (GA-crosslinked 17.89% and GSH-based 14.6%). GA-crosslinked CCM-HSA NPs showed a small particle size, low PdI, and demonstrated enhanced antiproliferative activity compared with free curcumin. These results provide design guidelines for engineering albumin-based nanocarriers with tailored stability and drug delivery performance.

24 February 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
WAWafa Al-Jamal
Wafa Al-Jamal
NLNa Li
Na Li
Human serum albumin (HSA) nanoparticles are promising drug carriers; however, robust control of their physicochemical and biological properties remains challenging. Here, we investigate how formulation parameters, mixing regime and crosslinking chemistry govern HSA nanoparticles’ biological performance. Glutaraldehyde (GA)-crosslinked HSA nanoparticles were first optimised using a bulk desolvation process by varying HSA concentration, pH and desolvation solvent. The formulation was then translated to a staggered herringbone micromixer to tune particle size via total flow rate and flow rate ratio. In parallel, a crosslinker-free route based on glutathione (GSH)-mediated disulfide reorganization, with or without H2O2, was developed, in which GSH transiently reduces intramolecular disulfide bonds and subsequent oxidation forms stabilising intermolecular disulfides. GA-crosslinked and GSH-mediated disulfide-crosslinked HSA nanoparticles were compared in terms of colloidal and serum stability, cytotoxicity and cellular uptake in 4T1 cells, and curcumin was encapsulated as a model hydrophobic drug. Both strategies produced physically stable nanoparticles, curcumin-loaded nanoparticles with good drug loading. In carrier-focused evaluations, GA-crosslinked HSA nanoparticles exhibited smaller sizes, negative charge, and high biocompatibility, with sustained cellular uptake and minimal serum-induced aggregation. In contrast, GSH-based HSA NPs were strongly cationic, exhibited faster initial cellular uptake, and underwent pronounced serum-mediated charge reversal, while showing comparable carrier cytocompatibility to GA-crosslinked NPs under the tested conditions. Using curcumin as a model hydrophobic payload, both formulations achieved effective drug encapsulation (GA-crosslinked 17.89% and GSH-based 14.6%). While GA-crosslinked CCM-HSA NPs showed a smaller particle size, lower PdI, and demonstrated enhanced antiproliferative activity compared with free curcumin. These results provide design guidelines for engineering albumin-based nanocarriers with tailored stability and drug delivery performance.